The New EU HTA Framework Creates New Evidence Requirements Since becoming applicable in January 2025, the EU Health Technology Assessment (HTA) Regulation has significantly increased the focus on patient-centered outcomes and real-world evidence as key components of reimbursement, market access, and healthcare decision-making across Europe
Some therapies, like NAD+, peptides, and certain injectables, do require a consultation and, in certain cases, lab work to make sure treatment is safe and appropriate
This improved dosing convenience is one of the practical advantages researchers appreciate about the formulation
However, it has no effect on the level of GPX4 [247]
Check current rules in your area before buying.
When to Use Each in Research BPC-157 may be more suitable for research involving: Gastrointestinal mucosal research (its origin and primary research domain) Musculoskeletal tissue repair studies (growing evidence base) Vascular biology and angiogenesis research Studies requiring acid-stable peptides Nitric oxide system investigations TB-500 may be more suitable for research involving: Wound healing and skin biology (T4s primary research domain) Cardiac tissue repair and regeneration Corneal research and ocular biology Cell migration and cytoskeletal dynamics studies Stem cell and extracellular vesicle research Practical Information Both compounds are supplied as lyophilized powders and reconstituted with bacteriostatic water
